{
  "item1": "recent Kidney Care sale given us enhanced flexibility deploy (or some cases redeploy) capital toward opportunities seek accelerate growth objectives, whether result innovation expanding portfolio geographically result channel expansion market development activities. Operational Excellence discussed above under “Recent Strategic Actions,” third quarter 2023, implemented new operating model intended simplify streamline operations better align manufacturing supply chain commercial activities. believe these changes will allow us more integrated nimble organization can respond more effectively operational challenges changes macroeconomic environment while enhancing ability drive innovation product portfolio. also continue focus increasing efficiencies through automation digitization.",
  "item7": "Emerging markets include sales operations Eastern Europe, Middle East, Africa, Latin America Asia (except Japan). Rest world includes sales operations Western Europe, Canada, Japan, Australia New Zealand. Percent change net sales constant currency rates non-GAAP financial measure. See section entitled “Non-GAAP Financial Measures” additional information about use measure.",
  "item2": "These forward-looking statements based certain assumptions analyses made light experience perception historical trends, current conditions, expected future developments well other factors believe appropriate circumstances. While these statements represent judgment what future may hold, believe these judgments reasonable, these statements not guarantees any events financial results. Whether actual future results developments will conform expectations predictions subject number risks uncertainties, including following factors, many which beyond control: ability achieve intended benefits recent strategic actions, including sale Kidney Care business, business strategy development activities (including acquisition Hillrom completion related integration activities) cost saving initiatives, future long-term financial improvement goals; impact global economic conditions (including, among other things, changes tariffs, taxation, trade policies treaties, sanctions, embargos, export control restrictions, potential recession, supply chain disruptions, inflation levels interest rates, financial market volatility, banking crises, war Ukraine, conflict Middle East other geopolitical events (and potential escalation these other conflicts), related economic sanctions being imposed globally response conflicts potential trade wars, global public health crises, pandemics epidemics, anticipation any foregoing, operations employees, customers, suppliers, foreign governments countries which operate) ability identify actions mitigate impact those conditions (or realize anticipated benefits any such mitigating actions); demand market acceptance risks for, competitive pressures (including pricing) related to, new existing products services (including customer response recent Novum LVP field actions related voluntary ship installation hold, which may include additional returns exchanges), challenges reputational risks associated converting customers new alternative products challenges accurately predicting changing customer preferences future expenditures inventory levels (including respect impact Novum LVP ship installation hold what company believes continuing fluid conservation practices) being able monetize new existing products services, impact those products services quality patient safety concerns, need ongoing training support products services; product development risks, including satisfactory clinical performance obtaining maintaining required regulatory approvals (including result evolving regulatory requirements withdrawal resubmission any pending applications), ability manufacture appropriate scale, general unpredictability associated product development cycle (which may result monetary penalties owed suppliers event do not place orders levels contemplated contractual arrangements); future actions of, failures act delays acting FDA, European Medicines Agency, any other regulatory body government authority (including SEC, DOJ, Health Canada Attorney General any state), any product quality patient safety issues (including those related company's infusion pump category) could delay, limit suspend product development, manufacturing, sale otherwise lead product recalls (either voluntary required governmental authorities), adverse regulatory site inspection reports, voluntary official action indicated classifications, labeling changes, launch delays, warning letters, import bans, refusal government grant government withdrawal approvals, clearances, licenses other marketing authorizations, denial import certifications, sanctions, seizures, injunctions (including halt manufacture distribution), monetary sanctions, criminal civil liabilities litigation; continuity, availability, pricing acceptable raw materials component parts, ability pass some all any increased costs customers through price increases otherwise, related continuity manufacturing, sterilization, supply distribution those suppliers; failure accurately forecast achieve short-and long-term financial performance goals, market category growth rates, growth rates segments, customer demand related impacts liquidity (including respect increased inventory levels); ability execute capital allocation plans, including debt repayment plans, timing amount any dividends, share repurchases divestiture proceeds; any future downgrades credit ratings ratings outlooks (including result Moody's review), withdrawals rating agencies rating us indebtedness, related impact funding costs liquidity; ability finance develop new products services, enhancements thereto, commercially acceptable terms all; actions tax authorities connection ongoing tax audits (including respect transfer pricing matters potential issuance one more NOPAs), outcome pending future litigation (including result customer supplier disputes) sufficiency any related reserves; fluctuations foreign exchange interest rates; impact any accounting estimates assumptions, including respect goodwill, intangible assets, other long-lived asset impairments operating results; failures respect quality, compliance ethics programs; ability attract, develop, retain engage key employees, including result organizational other corporate changes strategic initiatives, occurrence labor disruptions resulting labor disagreements under bargaining agreements national trade union agreements, disputes works councils otherwise; inability create additional production capacity timely manner occurrence other manufacturing, sterilization, supply difficulties, including result natural disaster severe weather event (such Hurricane Helene), war, terrorism, global public health crises epidemics/pandemics, regulatory actions, otherwise; future actions third parties, including third-party payors customers distributors (including group purchasing organizations (GPOs) integrated delivery networks); breaches breakdowns affecting information technology systems protected information, including cyber-attack, data leakage, unauthorized access theft, failures vulnerabilities information technology systems products; ability effectively develop, integrate deploy artificial intelligence, machine learning other emerging technologies into products, services operations manner compliant existing emerging regulations consistent evolving customer preferences; impact physical effects climate change, severe storms (including Hurricane Helene) storm-related events; changes legislation regulation other governmental pressures United States globally, including cost compliance potential penalties purported noncompliance thereof, including new amended laws, rules regulations well impact healthcare reform its implementation, suspension, repeal, replacement, amendment, modification other similar actions undertaken United States foreign governments, including respect pricing, reimbursement, taxation (including taxation income, whether respect current future tax reform) rebate policies; ability meet evolving varied corporate responsibility expectations stakeholders, including compliance emerging potentially contradictory global sustainability regulations; ability protect enforce patents other proprietary rights (including trademarks, copyrights, trade secrets, know-how) where patents third parties prevent restrict manufacture, sale, use affected products technology; Item 2. Management’s Discussion Analysis Financial Condition Results Operations COMPLETED STRATEGIC ACTIONS Since January 2023, completed several strategic actions, discussed below."
}